Alpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, supply risk, customer concentration, and control weaknesses take over.
References
Sources used in this report
SEC submissionsSEC submissions API for Alpha Cognition Inc.2026-05-13 · Issuer identity, CIK, SIC, exchange, fiscal year, emerging-growth-company status, and recent filing set.SEC XBRL companyfactsSEC companyfacts API for Alpha Cognition Inc.2026-05-13 · Official XBRL financial fact cross-check and taxonomy baseline.Annual reportFY2025 Form 10-K2026-03-31 · Business description, ZUNVEYL launch strategy, financial statements, liquidity, customer concentration, supply risk, risks, CMSI license, and controls.Earnings releaseFiscal 2025 financial results and operational update2026-03-26 · Q4 product revenue, bottles dispensed, prescriber growth, homes with prescriptions, PBM progress, study plans, cash, expenses, operating loss, and net loss.Quarterly reportQ3 2025 Form 10-Q2025-11-13 · Latest quarterly-report context before the FY2025 Form 10-K, interim launch trajectory, pre-October financing liquidity, and prior control weakness.Proxy statement2026 proxy statement2026-04-30 · Annual meeting agenda, director nominees, board independence, chair transition, audit committee, CBIZ appointment, Manning Elliott transition, and governance context.Current reportOctober 2025 public offering Form 8-K2025-10-02 · Offering structure, use-of-proceeds framing, sales expansion, marketing, payer coverage, reimbursement, and working-capital funding context.Current reportGalantos settlement Form 8-K2026-04-14 · Settlement of remaining contingent obligations under older Memogain-related arrangements.FDA labelZUNVEYL prescribing information2024-07-26 · Official indication, dosage forms, dosage strengths, warnings, contraindications, adverse reactions, and treatment boundary.